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What’s new 
 This is the first population-based study to quantify the impact of clinic context on 
glycaemic control of children with Type 1 diabetes in the UK using robust multilevel 
techniques. 
 We found significant differences between diabetes clinics over and above individual 
characteristics. However, clinic differences accounted for only a small portion of the total 
variation in glycaemic control and most of the variation was within clinics. This suggests 
that glycaemic improvements at a national level might best be achieved not only by 
targeting poor clinics but also by shifting the whole distribution of clinics to higher levels 
of quality. 
 Children who attended clinics with more consistent glycaemic results had significantly 
better glycaemic control. 
Abstract 
Aims: To determine the scope for improving children’s glycaemic outcomes by reducing 
variation between clinics and examine the role of insulin regimen and clinic characteristics. 
Methods: Cross-sectional analysis of 2012-13 National Paediatric Diabetes Audit data from 
21,773 children <19 years with Type 1 diabetes cared for at 176 clinics organised into 11 
regional diabetes networks in England and Wales. Variation in glycated haemoglobin 
(HbA1c) was explored by multilevel models with a random effect for clinic. The impact of 
clinic context was quantified by computing the % of total variation in HbA1c which occurs 
between clinics -Intraclass Correlation Coefficient (ICC).  
Results: Overall, 69 of the 176 diabetes clinics (39%) had a glycaemic performance which 
differed significantly from the national average after adjusting for patient case-mix with 
respect to age, gender, diabetes duration, deprivation and ethnicity. However, differences 
between clinics accounted for 4.7% of the total variation in HbA1c. Inclusion of within-clinic 
HbA1c standard deviation led to a substantial reduction in ICC to 2.4%. Insulin regimen, 
clinic volume, and diabetes networks had a small or moderate impact on ICC. 
Conclusions: Differences between diabetes clinics accounted for only a small portion of the 
total variation in glycaemic control. This implies that national glycaemic improvements 
might best be achieved not only by targeting poor centres but also by shifting the whole 
distribution of clinics to higher levels of quality.  
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Introduction 
The UK has the fourth largest paediatric diabetes population in Europe and the fifth largest 
population in the world (1, 2), with the most recent estimates indicating at least 29,000 
children under 19 years have T1D in the country (3, 4). Over the last decade, governmental 
bodies and national organisations have set specific standards of care and guidelines for 5 
children with diabetes in the UK (5-8). However, performance of England and Wales is poor 
when compared with similar European countries (9, 10). In 2012, less than one in five 
children and young people with diabetes in England and Wales met the NICE recommended 
HbA1c target of <58 mmol/mol (7.5%) (11). Results from the 2012 NHS Diabetes Atlas of 
Variation reported wide regional variations in diabetes outcomes for children thus addressing 10 
the issue of unwarranted variation in paediatric diabetes care (12). National audit reports 
have supported these findings by describing consistently large differences between paediatric 
diabetes clinics in England and Wales (13). Reduction of clinic variations was identified as a 
clear priority in the 2012 National Paediatric Diabetes Service Improvement Delivery Plan, 
which also set an aim to reduce national levels of HbA1c by 16 mmol/mol (1.5%) by 2023 15 
(14).  
Several multi-centre studies have looked at glycaemic differences between paediatric clinics 
(15-22). However, one major obstacle to effective policy action regarding unwarranted 
variation, as explored by previous studies, is that it is conceptualised as absolute differences 
between clinic means. Glycaemic outcomes can vary both between and within clinics. In 20 
addition to differences between clinics, we need to consider the share of the total variation in 
the glycaemic control that exists between clinics. This idea corresponds to the concept of 
clustering (23). Understanding how health outcomes are geographically clustered in the 
population is of crucial importance for policy development and implementation (24). For 
3 
 
example, if children’s metabolic control is uniformly achieved across clinics (low 25 
clustering), then policies aiming to reduce centre variation by targeting low performing 
clinics may narrowly miss most poorly controlled children in the country. Conversely, if 
glycaemic outcomes are heterogeneously distributed across clinics (high clustering), then 
policies that target all clinics in the country will see many resources inefficiently delivered to 
areas at the smallest need.  30 
The overall aim of the current study was therefore to determine the scope for improving 
children’s glycaemic outcomes by reducing variation between clinics. More specifically, the 
objectives were to describe the extent of variation in glycaemic control between and within 
clinics; explore the general contribution of clinics to understanding differences in children’s 
glycaemic outcomes; determine whether the influence of clinic context can be explained by 35 
differences in insulin regimen or other characteristics of the clinics, and investigate how 
clinic-level factors are associated with children’s metabolic control.  
Methods   
Study design and population 
We conducted a secondary analysis of nationwide data from the National Paediatric Diabetes 40 
Audit (NPDA) – the national audit of diabetes care for children and young people in England 
and Wales. Diabetes clinics are organised into 11 regional Paediatric Diabetes Networks (10 
in England plus Wales). The study included all children aged <19 years with type 1 diabetes 
who received care in paediatric diabetes clinics in England and Wales between April 1, 2012 
and March 31, 2013 (13). We included children with a duration of diabetes of at least 3 45 
months since levels of HbA1c immediately adjacent to diagnosis are not reflective of ongoing 
diabetes control. We excluded 251 children who changed clinic during the audit year and 
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children with missing information on age (n=3), gender (n=9), ethnicity (n=121), deprivation 
(n=190) and duration of diabetes (n=208). Clinics were included if they had at least 10 
children. The adoption of this threshold reflected the need to keep a balance between 50 
excluding as few clinics as possible and excluding clinics for which the amount of data was 
too small to be representative. One clinic with one eligible child was excluded leaving a final 
study population of 21,773 children across 176 clinics.  
NPDA has approval from the Confidentiality Advisory Group of the Health Research 
Authority to collect patient data under section 251 of the NHS Act 2006 (Reference No: 55 
ECC 2-03 (c)/2012). No additional ethics approval was required.  
Measures  
Outcome variable  
Glycaemic control was assessed by levels of HbA1c reported in standardised concentrations 
of mmol/mol in accordance with the International Federation of Clinical Chemistry (IFCC) 60 
(25). HbA1c values submitted to NPDA in Diabetes and Complications Trial (DCCT) units 
of percentage were converted to mmol/mol using the formula: IFCC (mmol/mol) = (10.93 × 
DCCT (%)) -23.50 (26). The mean HbA1c value over the audit year for each patient was used 
in the current analyses.  
Case-mix variables 65 
To ensure a fair comparison between clinics, we adjusted our analyses for glycaemic 
determinants which are beyond the control of the clinic without removing differences that 
may be attributable to the quality of diabetes care (27). These included age (continuous 
variable), gender, duration of diabetes (four categories: <1 year, 1 year, 2-4 years, and ≥ 5 
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years), ethnicity (6 categories: white, mixed, black, Asian, other, “not reported”), and 70 
deprivation (5 quintiles). Deprivation was derived by linking patient post codes to the 2010 
and 2011 Indices of Multiple Deprivation (IMD) for England (28) and Wales (29) 
respectively. We used small-area IMD as a proxy for individual socio-economic status. The 
IMD combines information from several domains (income, employment, education, health, 
housing and services, crime, and living environment) to produce a single score which is a 75 
relative ranking of small areas. An adjusted UK-wide IMD score was generated following 
established methodology (30). Interaction terms between age and diabetes duration 
contributed significantly to the explanatory power of the model and were retained in the 
models. 
Insulin regimen and clinic characteristics 80 
We considered four factors related to diabetes care; one measured at individual level (insulin 
regimen) and three at the level of the clinic (regional network, clinic volume, and within-
clinic glycaemic variability). Insulin regimen was classified by intensity as ≤3 
injections/day, ≥4 injections/day and insulin pump therapy. For each clinic we also 
computed three variables; these included the regional network to which the clinic belongs, 85 
the total number of eligible children being served by the clinic (clinic volume), and the 
standard deviation of HbA1c measurements (within-clinic HbA1c variability). Data for insulin 
regimen were missing for 2,933 children (13.5%). To minimize loss of information, missing 
data on insulin regimen were imputed using Multiple Imputation Chained Equations under a 
missing at random assumption (31). Imputed results were broadly similar to those using 90 
observed values (see supplemental File S1 for details on imputation model and complete 
case analysis); in the analysis examining the role of insulin regimen imputed findings are 
presented in this paper.  
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Statistical analysis 
We used a two-level multilevel model of children clustered within clinics to partition total 95 
variation in HbA1c into two components: variation between clinics and variation within 
clinics (i.e. between children). We also adjusted for children’s case-mix characteristics 
(gender, age, duration of diabetes, age-duration interactions, ethnicity, and deprivation 
quintile) as fixed effects. To visualise variation between adjusted clinic means, we used 
clinic estimates with 95% CI derived from the adjusted two-level model and plotted them 100 
against the national average. The above clinic estimates are akin to comparing clinics as if 
they had the same case-mix profile of children. Clinic estimates incorporate a “shrinkage 
factor” to correct for random variation, with less precise estimates from small clinics being 
weighted towards the national average. Clinics for which the upper 95% CI limit was lower 
than the national average were considered as performing “better than average”, while clinics 105 
whose lower 95% CI limit exceeded the national average were classified as “poorer than 
average”. Finally, clinics whose CI limits crossed the national average were categorised as 
“average”.  
To better understand the scope for improvements in glycaemic outcomes, we need to 
consider variation between clinics relative to the total variation, that is variation between and 110 
within clinics. Ascertaining the relative importance of clinics, after considering children’s 
case-mix characteristics, can provide important clues about how glycaemic control is 
distributed. To explore this, we calculated the Intraclass Correlation Coefficient (ICC) which 
represents the proportion of total variation in glycaemic control which occurs between 
clinics, i.e. 𝐼𝐶𝐶 =
𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑐𝑙𝑖𝑛𝑖𝑐 𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒
𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑐𝑖𝑛𝑖𝑐 +𝑤𝑖𝑡ℎ𝑖𝑛 𝑐𝑙𝑖𝑛𝑖𝑐 𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒
 (32). To illustrate the potential of a 115 
clinic-based approach to improve glycaemic control at a national level, we constructed a 
simple table by calculating the proportion of children with good (<58 mmol/mol; 7.5%), 
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moderate (58-80 mmol/mol; 7.5%-8.5%) and poor glycaemic control (>80 mmol/mol; 8.5%) 
in each of the three clinic classifications identified by the two-level case-mix adjusted model.   
Having established the share of total variation in HbA1c that exists between clinics, we then 120 
sought to investigate whether service-related factors could explain the “effect” of clinic 
context on individual glycaemic control. To explore this aspect, we extended the two-level 
case-mix adjusted model by separately introducing individual insulin regimen, regional 
network structure, clinic volume and clinic HbA1c-SD and looking at changes in ICC. 
Attenuation of the relative clinic effect was judged by reduction in ICC. We also examined 125 
how the above three clinic-level factors are related to children’s glycaemic outcomes. Clinic 
volume and HbA1c-SD were simultaneously entered in the model since larger clinics are 
more likely to exhibit greater variability. Inclusion of quadratic terms for clinic volume and 
HbA1c-SD did not improve model fit indicating that their association with glycaemic control 
was adequately described as linear.  130 
Parameters were estimated using the maximum likelihood method.  Model fit was examined 
by using the likelihood ratio test (LRT). Distribution of individual and clinic-level residuals 
were checked in all models and showed approximate normality. Statistical analyses were 
performed using Stata 13. 
Results  135 
Extent of variation in glycaemic control between and within clinics 
The characteristics of children and clinics are presented in Table 1. Clinic volume ranged 
from 34 to 398 children. Figure 1 shows how actual HbA1c levels vary both within and 
between the 176 paediatric diabetes clinics in England and Wales. The width of the box-and-
whisker plots shows the spread of individual HbA1c values within the clinics. The standard 140 
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deviation of individual HbA1c values ranged across clinics from 11 mmol/mol (1.0%) to 25 
mmol/mol (2.3%). Clinic means are represented by the red diamond and their spread around 
the national average value of 72 mmol/mol (8.8%) indicates the degree of variability that 
exists between clinics. Two things are worth noticing from this figure. First, glycaemic 
control varies more within than between clinics resulting in a considerable overlap between 145 
the clinic individual distributions. Second, clinics with poorer average glycaemic 
performance tend to have children with more variable glycaemic outcomes.  
Figure 2 shows the estimates of clinic means with 95% confidence intervals derived from the 
case-mix adjusted two-level model. On average, adjusted clinic means deviated around the 
national average by 3.5 mmol/mol (0.3%) (standard deviation of “clinic effect”). As shown 150 
in figure 2, clinics in the bottom 2.5% of the distribution had a glycaemic difference of 
around 14 mmol/mol [1.3%] as compared to clinics located at the top 2.5%. Overall, 69 of 
the 176 practices (39%) had an adjusted HbA1c value that deviated significantly from the 
national average. Of them, 34 practices performed below average and 35 performed above 
average.  155 
General contribution of clinics to total variation in glycaemic control 
To address the contribution of clinics in explaining variation in children’s glycaemic 
outcomes, the proportion of the total variation that is located between clinics (i.e. ICC) was 
calculated (Table 2). The unadjusted model showed that only 5.4% of the total variation 
occurred between clinics. After controlling for individual case-mix characteristics, ICC 160 
slightly reduced to 4.7%, with the remaining variation (95.3%) being located within clinics. 
Table 3 uses the multilevel typology to show how children with different levels of glycaemic 
control are distributed across clinics. Of the 5,333 children with a poor glycaemic control, 
1,546 (28%) received their care in one of the 35 poorly performing clinics. Although this is 
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higher than the 19% expected by chance, most poorly controlled children (72%) were treated 165 
by non-poorly performing clinics.   
Role of insulin regimen and clinic characteristics  
As sown in Table 2, ICC was only marginally affected when insulin regimen and clinic 
volume were fitted in the case-mix adjusted model (ICC slightly reduced to 4.2% and 4.5% 
respectively). Inclusion of network structure in the model led to a moderate reduction in ICC 170 
to 4.2%, however addition of networks did not give a better fit to the national data compared 
to the case-mix adjusted model (p-value of LRT=0.06). In contrast, addition of HbA1c-SD 
explained almost half of the clinic variability leading to a substantial reduction in ICC to 
2.4%. 
We further explored the association of HbA1c with clinic characteristics. Figure 3 shows 175 
mean network HbA1c values after controlling for children’s case-mix profile and clinic 
characteristics. Although some significant differences between networks are noticed (e.g. 
East Midlands and South Central vs East of England), overall, there is a substantial overlap 
in their confidence intervals.  
Figure 4 shows how clinic volume and clinic HbA1c-SD related to glycaemic outcomes after 180 
adjustment for case-mix characteristics and clinic differences. Children who attended larger 
clinics and clinics with more consistent glycaemic results (i.e. lower HbA1c-SD) had 
significantly better glycaemic outcomes. However, as shown by the difference in the slopes, 
the magnitude of the association was larger for HbA1c-SD (9.8 mmol/mol reduction in HbA1c 
(95% CI 8.2 to 11.5) per 10 mmol/mol (0.9%) decrease in clinic HbA1c-SD) compared to 185 
clinic volume (0.9 mmol/mol reduction in HbA1c (95% CI 0.2 to 1.5) per 100 children 
increase in clinic volume).  
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Discussion 
This study explored the importance of clinic context for understanding glycaemic differences 
in children with Type 1 diabetes. To convey the magnitude of potentially unwarranted 190 
variation between diabetes practices, we first examined glycaemic differences between 
clinics after adjusting for the case-mix composition of clinics. We also looked at the amount 
of variation that exists within clinics and expressed practice variation as a proportion of the 
total variability in glycaemic outcomes. This allowed us to better understand the scope for 
glycaemic improvements that might be possible by reducing variation between clinics.  195 
We explored the extent of clinic variation after controlling for patient case-mix and showed 
that two out of five practices had a glycaemic performance which differed significantly from 
the national average with some centres achieving better levels of glycaemic control than 
others. We also observed that practices with typically good glycaemic control had a 
glycaemic difference of 14 mmol/mol [1.3%] as compared to practices with a typically poor 200 
glycaemic performance. The above suggest that the magnitude of clinic variation is of 
clinical importance. Reduction of practice variations should be a strategic goal of diabetes 
systems to ensure optimal care is provided to all children with type 1 diabetes regardless of 
the clinic they attend.   
A second implication arises from the finding that clinics explained a small portion of the 205 
total variation in glycaemic control (i.e. 4.7%) and that most of the variation was within 
clinics and potentially attributable to unmeasured patient characteristics. Calculating the 
relative contribution of clinic differences as a share of the total variability in glycaemic 
control is important for policy making. For example, it is quite possible to have quite large 
differences between clinics and still show a low ICC if the variation that occurs within 210 
clinics is sufficiently large. This is precisely the situation revealed in our study. The health 
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policy implications of a low ICC were also illustrated by using a substantive typology of 
clinic’s glycaemic performance. We showed that interventions targeting only poor clinics 
would fail to capture most children in need because they are quite unvaryingly distributed 
across clinics. This suggests that nationwide improvements in glycaemic control might best 215 
be achieved not only by targeting poor performers but also by shifting the whole distribution 
of clinics to higher levels of quality. The recent change in NICE guidelines for children with 
T1D towards tighter HbA1c targets of less than 48 mmol/mol (6.5%) in 2015 (33) could 
potentially help towards this direction. Patient-centered policies have also been shown to 
facilitate whole system improvements (34). Here, the introduction of patient-reported 220 
experience measures (PREM) for paediatric diabetes care in England and Wales in 2013 (35) 
could be used as an effective tool to encourage local changes in all clinics, even those 
identified as performing well.    
To gain a better insight into how clinic context might impact on glycaemic outcomes we 
further examined the role of factors related to diabetes care. Firstly, we showed that insulin 225 
regimen had a small impact on ICC. This is consistent with other studies which also found 
that clinic differences could not be explained by type and dose of insulin treatment (16, 17, 
19). This suggests that aspects of diabetes care other than insulin regimens on offer might 
explain how clinics contribute to differences in children’s metabolic control. We also found 
that children treated in larger clinics had better glycaemic control, regardless of their case-230 
mix characteristics. This might reflect a tendency for larger clinic size to provide more 
specialised care, however, a reduction of 1 mmol/mol per additional 100 children was of 
little clinical significance. We also found that clinic size explained only a small proportion of 
the “clinic effect”. Taken together, the above findings suggest that there are unlikely to be 
any meaningful effects from centralisation of paediatric diabetes units into higher volume 235 
centres. 
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Our findings also showed that the contribution of regional networks on children’s glycaemic 
control was limited after controlling for children and clinic characteristics. However, it is 
important to emphasise that this finding does not indicate that regional networks have no 
important role to play in the way diabetes care is structured and delivered across clinics; 240 
instead networks might provide an efficient arena for the implementation of national 
guidelines and dissemination of interventions, such as encouraging young people and carer 
participation, broadening of stakeholder engagement, mapping resources and staffing levels, 
and identifying areas of service improvement (36).  
We explicitly modelled within-clinic variability as a clinic-level variable and found that 245 
children who attended clinics with more consistent glycaemic results had significantly better 
glycaemic control. This finding agrees with results from the Hvidore study group who 
reported better glycaemic performance in centres where the multidisciplinary team set 
consistent glycaemic targets (30). We also found that within-clinic variability explained half 
of the clinic differences. Glycaemic consistency requires focusing attention on management 250 
of challenging populations of children and echoes a broad range of factors related to diabetes 
care, including team cohesiveness, coordination of care and goal setting. Our data suggest 
that achievement of glycaemic consistency within a clinic could be used as a separate 
performance indicator in addition to average glycaemic levels.     
This is the first study to quantify the impact of clinic context on glycaemic control of 255 
children with Type 1 diabetes. We used a multilevel analytical approach which provides a 
robust framework for analysing hierarchical data. The large number of clinics provided high 
power to test for random effects. Also, the use of national audit data means the results of our 
study have strong external validity and are directly relevant to clinical practice.  
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Our results should be interpreted in the context of potential limitations. First, this was a 260 
cross-sectional analysis which precludes us from making any causal inferences. Although an 
effort was made to adjust for important glycaemic determinants which are exogenous to the 
clinic environment, other unmeasured factors such as family environment, parental 
education, prevalence of comorbidities, and health-risk behaviours were not taken into 
account. Moreover, since no individual-level indicators of socio-economic status were 265 
available, we used small-area deprivation as a proxy variable which might have led to 
residual confounding. In this regard, attribution of residual clinic differences to differences 
in quality of diabetes care should be done with caution (37). Second, the use of routinely 
collected data meant we had no control over potential errors during data collection or data 
entry. Third, some children attending the same clinic might also come from the same 270 
neighbourhood in which case clinic effects might also reflect the existence of underlying 
small-area effects. To explore this, cross-classified models were constructed, but the 
proportion of variance at the level of the clinic remained unaffected. Finally, although HbA1c 
measurements were based on standardised values, variation due to differences in laboratory 
methods between clinics cannot be excluded. 275 
Conclusion 
We analysed national audit data from children with Type 1 diabetes in England and Wales 
and found significant differences between diabetes clinics over and above individual 
characteristics. However, clinic differences accounted for only a small portion of the total 
variation in glycaemic control since most of the variation was within clinics. This implies 280 
that quality improvement might best be achieved not only by targeting poor centres but also 
by “shifting the curve” of overall paediatric diabetes practice towards higher quality levels. 
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Tables 
Table 1. Characteristics of children and diabetes clinics included in the study. 
 
No of children 
(%) 
Median % a (middle 50% 
range) across clinics 
Age (years)   
0-4 1,203 (5.5) 5.4 (4.0 to 6.8) 
5-11 7,656 (35.2) 35.1 (30.2 to 40.0) 
12-18 12,914 (59.3) 59.9 (54.3 to 64.5) 
Gender:   
Male  11,444 (52.6) 52.2 (49.4 to 55.6) 
Female  10.329 (47.4) 47.8 (44.4 to 50.6) 
Diabetes duration (years)   
< 1 3,606 (16.6) 16.4 (13.8 to 19.6) 
1  2,618 (12.0) 12.0 (10.3 to 14.0) 
2 - 4 6,628 (30.4) 30.0 (27.5 to 33.5) 
≥5 8,921 (41.0) 41.4 (37.4 to 44.9) 
Index of multiple deprivation 
quintile b 
  
1 (least deprived) 4,359 (20.0) 16.1 (7.1 to 26.3) 
2 4,354 (20.0) 19.4 (13.8 to 26.3) 
3 4,354 (20.0) 19.4 (14.6 to 24.6) 
4 4,352 (20.0) 20.1 (13.7 to 26.4) 
5 (most deprived)  4,354 (20.0) 15.1 (8.3 to 29.6) 
Ethnicity   
White 17,317 (79.5) 90.5 (68.1 to 97.8) 
Asian  1,083 (5.0) 1.1 (0 to 6.0) 
Mixed  575 (2.6) 1.4 (0 to 3.2) 
Black 409 (1.9) 0 (0 to 1.1) 
Other 305 (1.4) 0 (0 to 1.3) 
Not reported 2,084 (9.6) 0 (0 to 6.5) 
Insulin regimen   
≤ 3 daily injections 2,825 (13.0) 5.6 (1.2 to 17.6) 
≥ 4 daily injections 12,761 (58.6) 66.8 49.6 to 79.8) 
Insulin pump therapy 3,254 (15.0) 12.8 (1.3 to 24.8) 
Missing  2,933 (13.5) 0 (0 to 2.5) 
Overall  21,773 - 
a Percentage of children in each group were calculated for each clinic. 
b A UK-wide index of multiple deprivation score for both England and Wales was developed 
using England as a reference population and following methodology described by Payne and 
Abel (2012) 
Note: percentages may not add up to 100 due to rounding.  
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Table 2. Proportion of variance in children’s glycaemic control attributable to differences between clinics 
 
Unadjusted 
model a 
Case-mix 
adjusted 
model b 
Case-mix 
adjusted + 
insulin regimen c  
Case-mix 
adjusted + 
clinic volume  
Case-mix 
adjusted + 
networks d  
Case-mix 
adjusted + clinic 
HbA1c-SD  
Components of variance in HbA1c Variance (SE) Variance (SE) Variance (SE) Variance (SE) Variance (SE) Variance (SE) 
Between clinics 16.4 (2.1) 12.4 (1.6) 11.8 (1.5) 11.9 (1.5) 11.0 (1.4) 6.0 (0.9) 
Within clinics  287.6 (2.9) 249.5 (2.4) 246.6 (2.4) 249.5 (2.4) 249.5 (2.4) 249.5 (2.4) 
% of total variance attributable to 
differences between clinics - ICC 
5.4% 4.7% 4.6%  4.5% 4.2%  2.4% 
-2Log likelihood  185,408 182,295 - 182,290 182,277 182,195 
Two-level models with a random effect for clinic. SE=standard error, ICC=Intraclass Correlation Coefficient. 
a No explanatory variables 
b Adjusted for age, gender, diabetes duration, age-duration interaction, ethnicity, and deprivation 
c  Data for insulin regimen were missing for 2,933 children (13.5%) and were imputed using multiple imputation 
d 11 regional diabetes networks  
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Table 3. Number of children (%) with different levels of glycaemic control by clinic glycaemic performance  
 
 
 
 
 
 
 Clinic glycaemic performance   
Individual HbA1c  
Better than 
average (n=34) 
Average   
(n=107) 
Poorer than 
average (n=35) 
Total 
<58 mmol/mol (7.5%) 1,389 (36%) 2,022 (52%) 474 (12%) 3,885 
58-80 mmol/mol (7.5%-8.5%) 3,178 (26%) 7,122 (58%) 2,055 (17%) 12,355 
>80 mmol/mol (8.5%) 848 (15%) 3,139 (57%) 1,546 (28%) 5,533 
Note: percentages refer to the total number of children in each glycaemic category and may not add up to 100 due to 
rounding.  Classification of clinics into categories is based on the 95% confidence intervals of the clinic estimates obtained 
from the case-mix adjusted two-level model. Adjustment was made for individual gender, age, duration of diabetes, ethnicity, 
and deprivation. 
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Figures 
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Figure 1. Box and whisker plots showing variation in HbA1c within each of the 176 diabetes clinics in England and Wales. Clinics are ranked 
according to their crude mean HbA1c (blue diamonds). Clinic means vary around the national average of 72 mmol/mol (8.8%) as represented by the 
red horizontal line. Dashed line represents the NICE HbA1c recommended target at the time of the study. Individual outlying HbA1c values are not 
shown. 
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Figure 2. Estimates of clinic means with 95% confidence intervals after adjustment for differences in case-mix characteristics of children regarding 
age, gender, diabetes duration, ethnicity, and deprivation. Estimates derived from a two-level model with a random effect for clinic. Clinics are 
ranked according to their mean HbA1c using the average HbA1c value as a reference (red horizontal line). Dashed line represents the NICE HbA1c 
recommended target at the time of the study. 
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Figure 3. Predicted mean HbA1c levels for the 11 Paediatric Diabetes Networks after adjusting for individual case-mix characteristics 
(age, gender, diabetes duration, ethnicity, and deprivation) and differences between clinics.  
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Figure 4. Association between within-clinic variability (HbA1c-SD), clinic volume and predicted HbA1c levels. Results from two-level model 
with a random effect for clinic, adjusted for case-mix characteristics (age, gender, diabetes duration, ethnicity, and deprivation). Clinic volume 
and clinic HbA1c-SD entered simultaneously in the model.  
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